AlzeCure in-licenses Acturum asset in neuropathic pain

CNS specialist AlzeCure Pharma (FN STO: ALZCUR) has exclusively in-licensed a vanilloid receptor subtype 1 (VR1) project targeting neuropathic pain from fellow Swedish company Acturum Life.

The project is in the clinical development phase, and AlzeCure's aim is to develop a new topical local treatment for neuropathic pain. The mechanism of action of the project is via VR1 receptors, which have a key role in pain signaling.

"Our clinical pain experts see that we may have the opportunity to attack neuropathic pain in a whole new way"No upfront payments are necessitated by the agreement, which covers all indications for the global market. No milestone payments are due before clinical Phase II studies are initiated.